

Zvezdan Pirtosek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5027004/publications.pdf>

Version: 2024-02-01

71
papers

1,661
citations

331670

21
h-index

302126

39
g-index

75
all docs

75
docs citations

75
times ranked

2215
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2022, 16, 118-129.	2.1	7
2	Headache Because of Problems with Teeth, Mouth, Jaws, or Dentures in Chronic Temporomandibular Disorder Patients: A Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3052.	2.6	2
3	Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the <scp>OBSERVE-PD</scp> observational study. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 167-176.	2.1	3
4	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. <i>Journal of Neural Transmission</i> , 2021, 128, 321-335.	2.8	37
5	Preserved cholinergic forebrain integrity reduces structural connectome vulnerability in mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2021, 425, 117443.	0.6	2
6	Long-term effect of bilateral STN-DBS on non-motor symptoms in Parkinson's disease: A four-year observational, prospective study. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 13-16.	2.2	21
7	Quantitative EEG and cholinergic basal forebrain atrophy in Parkinson's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2021, 106, 37-44.	3.1	10
8	Abnormal metabolic brain network in behavioral variant of frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
9	Progression of metabolic brain patterns in common dementias. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
10	Identification and validation of Alzheimer's disease-related metabolic pattern in patients with pathologically confirmed Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042629.	0.8	3
11	Preserved cholinergic forebrain structure reduces the impact of strategic lesions to the connectome in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e043882.	0.8	0
12	Atypical clinical presentation of pathologically proven Parkinson's disease: The role of Parkinson's disease related metabolic pattern. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 1-3.	2.2	4
13	Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patterns-based approach. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2901-2910.	6.4	23
14	Update on the Management of Parkinson's Disease for General Neurologists. <i>Parkinson's Disease</i> , 2020, 2020, 1-13.	1.1	33
15	Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. <i>Biomedicine Hub</i> , 2020, 5, 1-22.	1.2	7
16	Sex differences in Parkinson's disease: A transcranial magnetic stimulation study. <i>Movement Disorders</i> , 2019, 34, 1873-1881.	3.9	14
17	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 353-365.	3.9	126
18	Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 50.	7.2	22

#	ARTICLE	IF	CITATIONS
19	Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurology, 2019, 19, 50.	1.8	74
20	Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease. Frontiers in Pharmacology, 2019, 10, 8.	3.5	39
21	Semi-Automatic Signature-Based Segmentation Method for Quantification of Neuromelanin in Substantia Nigra. Brain Sciences, 2019, 9, 335.	2.3	9
22	Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other α -Synucleinopathies. Frontiers in Neurology, 2019, 10, 1204.	2.4	13
23	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology, 2018, 265, 856-862.	3.6	51
24	An updated diagnostic approach to subtype definition of vascular parkinsonism – Recommendations from an expert working group. Parkinsonism and Related Disorders, 2018, 49, 9-16.	2.2	55
25	ICM-D045: SIMILAR METABOLIC BRAIN CHARACTERISTICS OF DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P45.	0.8	0
26	P3-364: SIMILAR METABOLIC BRAIN CHARACTERISTICS OF DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1227.	0.8	0
27	The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinson's disease. Physica Medica, 2018, 52, 104-112.	0.7	10
28	Similar effect of intermittent theta burst and sham stimulation on corticospinal excitability: A 5-day repeated sessions study. European Journal of Neuroscience, 2018, 48, 1990-2000.	2.6	25
29	Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease. Npj Parkinson's Disease, 2018, 4, 14.	5.3	70
30	Sensory Trick in Levodopa-Induced Orolingual Dystonia in a Patient with Advanced Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 136-137.	1.5	4
31	Hypometric anticipatory postural adjustments in dystonia are not affected by deep brain stimulation of globus pallidus internus. Neuroscience Letters, 2017, 636, 151-157.	2.1	1
32	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.8	32
33	Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample. Neuroradiology, 2017, 59, 507-515.	2.2	55
34	The P3 cognitive ERP has at least some sensory modality-specific generators: Evidence from high-resolution EEG. Psychophysiology, 2017, 54, 416-428.	2.4	14
35	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	2.2	149
36	[ICM-D035]: MONITORING THE PROGRESSION OF DEMENTIA USING FDG-PET BRAIN IMAGING AND NETWORK ANALYSIS: ROLE OF THE ALZHEIMER'S DISEASE-RELATED PATTERN. Alzheimer's and Dementia, 2017, 13, P31.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. <i>ENeurologicalSci</i> , 2017, 8, 44-53.	1.3	10
38	The diabetic brain and cognition. <i>Journal of Neural Transmission</i> , 2017, 124, 1431-1454.	2.8	77
39	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. <i>Journal of Neurology</i> , 2017, 264, 112-120.	3.6	32
40	[ICaPâ€025]: THALAMIC CONNECTIVITY CONTRIBUTES TO EPISODIC MEMORY IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P24.	0.8	0
41	[P1â€391]: MONITORING THE PROGRESSION OF DEMENTIA USING FGDâ€PET BRAIN IMAGING AND NETWORK ANALYSIS: ROLE OF THE ALZHEIMER'S DISEASEâ€RELATED PATTERN. <i>Alzheimer's and Dementia</i> , 2017, 13, P416.	0.8	1
42	[P2â€299]: THALAMIC CONNECTIVITY CONTRIBUTES TO EPISODIC MEMORY IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P731.	0.8	0
43	P1-252: Characteristic Metabolic Brain Pattern in Slovenian Alzheimer's Disease Patients with Low CSF Beta-Amyloid. , 2016, 12, P505-P506.		0
44	Processing complex pseudo-words in mild cognitive impairment: The interaction of preserved morphological rule knowledge with compromised cognitive ability. <i>Clinical Linguistics and Phonetics</i> , 2016, 30, 49-67.	0.9	28
45	IC-P-078: Correlation between metabolic and CSF biomarkers in Alzheimer's disease patients with early cognitive decline. , 2015, 11, P56-P57.		1
46	Suicide in <sc>P</sc>arkinson's <sc>D</sc>isease <sc>P</sc>atients <sc>T</sc>reated <sc>W</sc>ith <sc>L</sc>evodopaâ€<sc>C</sc>arbidopa <sc>I</sc>ntestinal <sc>G</sc>el. <i>Movement Disorders</i> , 2015, 30, 1434-1435.	3.9	10
47	Blurred boundaries between organic and functional etiology: A man with a jerky leg. <i>Journal of the Neurological Sciences</i> , 2015, 354, 122-123.	0.6	0
48	Postural stability under globus pallidus internus stimulation for dystonia. <i>Clinical Neurophysiology</i> , 2015, 126, 2299-2305.	1.5	11
49	P3-152: Correlation between metabolic and CSF biomarkers in Alzheimer's disease patients with early cognitive decline. , 2015, 11, P685-P686.		0
50	Euro<sc>I</sc>nf: <sc>A</sc><sc>M</sc>ulticenter <sc>C</sc>omparative <sc>O</sc>bservational <sc>S</sc>tudy of <sc>A</sc>pomorphine and <sc>L</sc>evodopa <sc>I</sc>nfusion in <sc>P</sc>arkinson's <sc>D</sc>isease. <i>Movement Disorders</i> , 2015, 30, 510-516.	3.9	203
51	Dopaminergic medication alters auditory distractor processing in Parkinson's disease. <i>Acta Psychologica</i> , 2015, 156, 45-56.	1.5	22
52	Family history based approach in risk prediction for Parkinson's disease: Additional contribution of familial associated disorders. <i>Genetika</i> , 2015, 47, 303-310.	0.4	0
53	Wavelet Analysis Increases Sensitivity and Specificity of Spirography for Ambulatory Tremor Discrimination. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	2
54	IC-P-146: THE ASSOCIATION BETWEEN CSF AND FDG/PET IMAGING BIOMARKERS OF NEURODEGENERATION IN MILD COGNITIVE IMPAIRMENT. , 2014, 10, P84-P84.		0

#	ARTICLE	IF	CITATIONS
55	P2-093: THE ROLE OF NEUROPSYCHOLOGICAL ASSESSMENT IN PREDICTING CSF DEMENTIA MEASURES IN MILD COGNITIVE IMPAIRMENT. , 2014, 10, P505-P505.		1
56	Cognition in late onset depression. Psychiatry Research, 2013, 210, 89-94.	3.3	3
57	Elicitation of neurological knowledge with argument-based machine learning. Artificial Intelligence in Medicine, 2013, 57, 133-144.	6.5	18
58	The syndrome of deafness–dystonia: Clinical and genetic heterogeneity. Movement Disorders, 2013, 28, 795-803.	3.9	25
59	A case of multiple system atrophy with normal dopamine transporter imaging. Journal of Neurology, 2012, 259, 2729-2731.	3.6	6
60	ABML Knowledge Refinement Loop: A Case Study. Lecture Notes in Computer Science, 2012, , 41-50.	1.3	2
61	Elicitation of Neurological Knowledge with ABML. Lecture Notes in Computer Science, 2011, , 14-23.	1.3	2
62	Tremor amplitude and tremor frequency variability in Parkinson’s disease is dependent on activity and synchronisation of central oscillators in basal ganglia. Medical Hypotheses, 2010, 74, 362-365.	1.5	15
63	Gene expression changes in blood as a putative biomarker for Huntington's disease. Movement Disorders, 2009, 24, 2277-2281.	3.9	28
64	Light chain deposition disease restricted to the brain: the first case report. Human Pathology, 2007, 38, 179-184.	2.0	34
65	Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Movement Disorders, 2005, 20, 937-944.	3.9	113
66	Event-related potentials elicited by distractors in an auditory oddball paradigm in schizophrenia. Psychiatry Research, 2005, 137, 49-59.	3.3	13
67	Neuroprotection and Dopamine Agonists. Advances in Experimental Medicine and Biology, 2004, , 55-74.	1.6	8
68	Attention and cognition in bradykinetic-rigid syndromes: An event-related potential study. Annals of Neurology, 2001, 50, 567-573.	5.3	39
69	Attention and cognition in bradykinetic-rigid syndromes: An event-related potential study. Annals of Neurology, 2001, 50, 567.	5.3	1
70	Botulinum Toxin in the Treatment of Neurological Disorders. Annals of the New York Academy of Sciences, 1994, 710, 76-87.	3.8	9
71	Cardiovascular reflexes in Parkinson's disease: Effect of domperidone and apomorphine. Clinical Autonomic Research, 1992, 2, 215-219.	2.5	17